

R&D Strategy Bridging the academia-industry gap

Duncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline

GSK at a glance Who we are

We are a science-led global healthcare company. Our mission is to improve the quality of human life by enabling people to do more, feel better and live longer.





What we do





Pharmaceuticals

We develop and make medicines to treat a range of conditions including: respiratory diseases, cancer, heart disease, epilepsy, bacterial and viral infections such as HIV and lupus, and skin conditions like psoriasis.



Vaccines

We research and make vaccines for children and adults that protect against infectious diseases, including: influenza, rotavirus, cervical cancer, measles, mumps, rubella, hepatitis, polio, tetanus and meningitis.



Consumer Healthcare

We make innovative consumer products in four categories of Total Wellness, Skin Health, Oral Care and Nutrition.

Where we are




We are a global company operating in more than 115 countries. We have a network of 87 manufacturing sites and key R&D centres in UK, USA, Spain, Belgium and China.





The pressures on industry continue...





GSK R&D Strategy



A Different Pharma Model

Integrated with the scientific and research community





Diverse Partnerships Integral to Our Success





Discovery Partnerships with Academia (DPAc) A collaborative approach from GSK



"everyone playing to their strengths"



Build integrated partnerships that can translate innovative research into medicines that benefit patients

Key elements of DPAc



Focus on the medicine

- Collaborative partnerships focussed on drug discovery
- Starts at any point from initiation of early screening, finishes with the medicine

Undertake the best science

- Minimal infrastructure undertake projects independent of location or disease area
- Access to all GSK drug discovery and development capabilities

Share in the investment, share in the reward

- Both sides contribute looks for a complementary match of skills where GSK can make a positive contribution to success
- Milestone funding with royalties. If GSK stops then the academic is free to continue and progress

What we look for



Clear Therapeutic hypothesis	A coherent and supportable hypothesis that modulation of target will produce a physiological effect which will be of therapeutic benefit to particular patients
Target defined	Specific drug target identified, and some understanding of type of pharmacology desired
(Exclusive) enabling expertise	Academic partner has know-how and/or expertise essential to progressing the target which is not (readily) found elsewhere
Tractability	Target knowledge suggests that a drug-like molecule can be generated Disease knowledge suggests that opportunity can be evaluated effectively in the clinic
Requirement for GSK contribution	GSK has capabilities and expertise which will help progress the project to the next milestone


What are GSK's capabilities?



HTS capacity Medicinal chemistry Large scale protein Selectivity PK-PD 2 million and computational molecular modelling production screening compound set design 4 1400-02 n 2 0 6 8 10 Time Lead **Early Lead** Target Assay Late Lead Identification **Feasibility** Development **Optimisation Optimisation** scinovo Preclinical Flexible, Encoded Library Synthetic & Biopharm discovery **Biopharm affinity** Development high tech assay technology analytical platforms (safety, chemistry, maturation platforms >10 billion compounds chemistry pharmacy)


Shared activities between academia and GSK early stage





Examples of projects in Europe








- An opportunity to collaborate together to test our compound collection using our pharmacological screening platforms to discover active compounds
- We will share key results from the screen to provide you with the best possible chemical probes to interrogate your translational biological assays



How does Discovery Fast Track work?



- The researcher provides a novel drug discovery concept that may include assay protocols, tools, reagents and models
- GSK provides a team of scientists and its state-of-the-art capabilities to scale up and industrialize assays and data analysis
- The target is screened against GSK compound collections and enabled to find novel quality pharmacologically active compounds
- Discovery Fast Track is running in Europe in 2014



www.gsk.com/discoveryfasttrack



In summary.....



Discovery Partnerships with Academia

building industry – academia collaborations in drug discovery



